






SARSUAG ENTERPRISES





Solutions for Life Science Research

March 2018




Sarsuag Enterprises



Science-focused biotechnology company established in 2016.






Offering value-added contract research services for Life Sciences R&D.

Founder of company have 15 years of experience in Biotech and CRO Industries



Cutting-edge science providing fast solutions with best-in-class quality.





Contract Research Offerings



Assays for Biologics R&D

Basic Services

- Bioavailability and functional Assays
- Host-Cell Protein and other impurity detection Assays
- Pilot-scale immune-response checking
- Molecular Biology Services
- Immunology Services

Companion Products

- Secondary Antibodies
- Anti-Tag Antibodies



Immunology Services: Antibody Development

Custom Antibodies against Protein, Peptides, and mixture of proteins

Polyclonal Antibody Antibodies in Rabbit and Goat Monoclonal Antibody Hybridoma Development in Mouse

Antibody Purification Affinity Purification – Protein A/G Antigen-affinity for Mono-specific pAbs Double-affinity purification (for modified peptides)

Example: Dilution curve of antibody clones to demonstrate relative affinity


Capability Highlights

- ✓ Analysis-driven development process all antigens do not have same immune response
- \checkmark Faster development for immunogenic antigens
- \checkmark Multitude of purification columns to optimize yield and affinity

Immunology Services: Antibody Characterization

Immuno-assay Development

- •Western Blot
- •Immuno-precipitation
- Immuno-cytochemistry
- •Immuno-histochemistry (on human and animal tissues)
- •Immuno-Fluorescence
- Sandwich ELISA Pair Determination and Prototyping



Antibody Conjugation With HRP, FITC, Biotin, ALPor any other conjugate / fluorophore

Example: IHC of Thyroglobulin and EMAantibody on human tissues






We have relationship with clinics in Bangalore and Chennai for sourcing human samples

Immuno-Purification

Purification from serum on Protein-Aor Antigen-specific columns





Assays for Biologics R&D

Bioavailability and Functional Assays

- Custom-designed antibodies and immunoassays to detect the product in serum at a specified limit
- Other functional immunoassays for product characterization

Process-Related Impurity Detection Assays

- Custom-designed antibodies and immunoassays for Host-Cell Protein detection
- Hybridization-based assays for Host-Cell DNA detection
- Custom immunoassays for other processderived contaminants such as growth factor, media etc

Immunogenicity assay for Testing Clinical Samples

- Development of reagents for Assay
- Development and Validation of Immunogenicity Assay
- Analysis of Clinical samples in GLP Environment



Process-Related Impurity Detection

□For any biopharmaceutical product, the purification process of the target active protein may co-purify other contaminants from the cell

□Such contaminants may have immunogenic properties affecting the patient safety and product consistency

□ Need an assay system to detect contaminants such as:

- Host Cell Protein
- Host Cell DNA
- Growth factors and other media used in cell culture

These impurities are characteristics of the process and not of the product itself



Process-related Impurities: Regulatory View

Excerpt from ICH Q6B (Test Procedure and Acceptance Criteria forBiotechnological Products)

"Cell substrate-derived impurities include, but are not limited to, <u>proteins</u> derived from the host organism, <u>nucleic acid</u> (host cell genomic, vector, or totalDNA).

"For host cell proteins, a sensitive assay e.g., <u>immunoassay</u>, capable of detecting a <u>wide range</u> of protein impurities is generally utilized. In the case of an immunoassay, a polyclonal antibody used in the test is generated by immunization with a preparation of a production cell minus the productcoding gene, fusion partners, or other appropriate celllines.

"The level of DNA from the host cells can be detected by direct analysis on the product (such as <u>hybridization</u> techniques).

"<u>Clearance studies</u>, which could include spiking experiments at the laboratory scale, to demonstrate the removal of cell substrate-derived impurities such as nucleic acids andhost cell proteins may sometimes be used to eliminate the need for establishing acceptance criteria for these impurities. "



Process-related Impurity Detection : Our Offerings

Host-Cell Protein

- Polyclonal antibody development (validation using 1D and 2D SDS-PAGE)
- Assay in Western
 Blot or ELISAformat
- Validation in Spiked Recovery Assay

Host-Cell DNA

- PCRamplification using Random Primers
- Detection using hybridization (with DIG-labeled probe)
- Validation in Spiked Recovery Assay


Culture Contaminants

- Custom immunoassay against specific contaminant
- E.g. we already have a Sandwich ELISAassay for Insulin
- Validation in Spiked Recovery Assay

Assay strategies that have been generally acceptable to FDA biotechnology product reviewers

HCPAntibody Development








Method Validation

			 _
and the second second			
-			
-			
-			

Antigen Depletion

- Run depleted immunogen at the end of each round on SDSPAGE
- Silver stain and compare with original immunogen to validate antigen depletion



Antibody Response

- Run original immunogen in multiple lanes and do western blotting at the end of each round with collected antisera
- Appearance of new bands in Western Blot validates antibody response for less immunogenic antigens in host cell sample




Completeness

- Run original immunogen in 2D gel and do western blotting at the end of each round with collected antisera
- Appearance of new spots in Western Blot validates antibody response for less immunogenic antigens in host cell sample



Antigen depletion of Immunogens

Silver staining of 15% SDS PAGE




Lane 1: Total cell lysate- $50 \mu g$ Lane 2: 1st Depletion – $50 \mu g$, Lane 3: 2ndDepletion – $50 \mu g$, Lane 4: 3rdDepletion- $50 \mu g$.

- 1. Passage over anti-HCP column depletes highly immunogenic proteins (★)
- 2. Less immunogenic Proteins (\rightarrow) are not depleted and is enriched by sequential passage over the anti-HCP column
- 3. During sequential depletions, the number of differential loss of protein bands decreases.
- 4. Depletion using the third bleed anti-HCP column did not show significant loss of protein bands as compared to the second depletion, indicate the depletion of all immunogenic proteins is complete.



Cascade Immunizations

1-D Western Analysis



Lane 1: 100 µg total HCPdetected with 1st bleed anti-HCP antibody Lane 2: 100 µg total HCPdetected with 1-3rd pooled bleed anti-HCP antibodies


For detection HRPconjugated anti-Rabbit secondary antibodies were used and blot developed using DAB

Three sequential depletions resulted in at least two-fold increase in the number of proteins against antibodies were raised



Antibody response is sustained through Cascade Immunization schedule

1 D western analysis



Lane 1: 100ug total HCP detected with pooled 1-3rd bleed anti-HCP antibody Lane 2: 100ug total HCP detected with 3^{rrd} bleed anti- HCP antibodies For detection HRP conjugated anti-Rabbit secondary antibodies were used and blot developed using DAB


The profile of protein bands detected by the 3rd bleed antibodies is similar to that observed by the pooled 1st - 3rd bleed antibodies

Immunogenicity Assay for clinical Development of Biosimilars

ELISA



- Development and Validation of Method \triangleright according to EMEA and FDA guideline.
- Analysis of Samples in GLP controlled environment.
- Development and validation of Method for Neutralizing Antibodies.



PLOTE STATES

Read Horat

PHARMACOKINETICS ASSAY FOR BIOSIMILARS

Pharmacokinetic Assays

We have industry leading experience in development and Validation of PK/TK assay for large molecules and peptides.

- Develop and validate assays that have analytical ranges which appropriate for the study samples.
- Develop assay that are both specific and sensitive
- Provide support for critical reagent generation and purification including the generation of antibodies to be used for capture and detection reagents.
- Assess method feasibility in multiple technology platforms.



Sarsuag's Innovate assay methods to address even most challenging requirements.

- **Cell-based assay**
- ADCC & CDC
- Reporter ADCC
- Potency

Binding Assays

- Target Affinity (SPR & ITC)
- Target Binding ELISA
- Target Cellular Binding





Bioanalytical Method for Biosimilar/Biologics

Parameter	Assay
Identity	SDS-PAGE (non-reduced; EP) Western-Blot
	Peptide map
	N-terminal sequencing
Purity / Integrity(Degradation or	SDS-PAGE (reduced)Western-Blot and HP-
aggregation products)	SEC
Isoforms(EP)	IEF
Content	ELISA
	OD 280/320 nm
Glycosylationpattern	HPAEC-PAD (native oligosaccharides;
	neutralstructures)
Endotoxin	LAL
Potency	Bio assay



Parameter	Assay
Monomer content	HPLC-SEC (EP) or Gel filtration reduced
Primary structure	ESI-MS
Tertiary structure	CD spectrum
Site specific glycosylation	ESI/TOF-MS; MALDI/TOF-MS
Oxidation analysis	LC-ESI-MS
MethionineOxidation	RP-HPLC or Peptide Map
N-terminal sequence	ESI-MS, ESI-MS-MS or Edman N terminal seq
C-terminal heterogeneity	Carboxypeptidase
Tryptic Peptide Mapping(EP)	HPLC

TOXICOLOGY STUDY THROUGH OUR PARTNER (Liveon Biolabs)



* * * *	General Toxicology Acute Toxicity Sub Acute Toxicity Sub Chronic Toxicity Chronic Toxicity	 Special Toxicity Toxicokinetics Antibacterial activities Carcinogencity Immunotoxicology 	Biocompatibility Studies(Medical Devices)* Cytotoxicity* Skin Sensitization* Acute Systemic Toxicity
 <td>Local Irritation Dermal Irritation Local Lymph Node Assay Photosensitivity Skin Irritation Skin Sensitization</td><td> Genetic Toxicity AMES Micronucleus Assay (In vivo) Chromosomal Aberration (in-vivo and in-vitro) Cytotoxicity </td><td> Subchronic Toxicity Chronic Toxicity Irritation / Intracutaneous Reactivity Genotoxicity </td>	Local Irritation Dermal Irritation Local Lymph Node Assay Photosensitivity Skin Irritation Skin Sensitization	 Genetic Toxicity AMES Micronucleus Assay (In vivo) Chromosomal Aberration (in-vivo and in-vitro) Cytotoxicity 	 Subchronic Toxicity Chronic Toxicity Irritation / Intracutaneous Reactivity Genotoxicity
* * * *	Reproduc Prenatal Developmental One-Generation Reproduct Two-Generation Reproduct Reproduction-Developmen	tion	 Implantation Hemocompatibility Carcinogenicity Reproductive Toxicity

Note : We have Partner in Canada and USA to conduct toxicology study in Monkey

Antibodies for Biosimilars Development



Rabbit anti-Trypsin	: SS-I-110-A
Rabbit Anti-Trypsin-HRP	: SS-I-110-B
Rabbit Anti Human TNF alpha Antibody	: SS-I-111
Rabbit Anti Etanercept Antibody	: SS-I-112
Anti Rituximab Monoclonal Antibody	: SS-I-113
Rabbit Anti Adalimumab Antibody	: SS-I-114
Anti TNF alpha Monoclonal Antibody	: SS-I-115
Rabbit Anti-Bevacizumab Antibody	: SS-I-116
Anti-GCSF Monoclonal Antibody	: SS-I-117
Anti-PEG Monoclonal Antibody	: SS-I-118
Anti-h Alpha Subunit Monoclonal Antibody	: SS-I-119
Anti-hCG Monoclonal Antibody	: SS-I-120
Anti-FSH Monoclonal Antibody	: SS-I-121
Anti-LH Monoclonal Antibody	: SS-I-122
Rabbit Anti-Ranibizumab Antibody	: SS-I-123
Rabbit Anti-Rituximab Antibody	: SS-I-124
Rabbit Anti-Trastuzumab Antibody	: SS-I-125
Rabbit Anti-Liraglutide Antibody	: SS-I-126



IMMUNOGENICITY ELISA KITS

Etanercept (Enbrel) Immunogenicity KIT (SS-E-101) Rituximab (Mabthera) Immunogenicity KIT (SS-E-102) Bevacizumab (Avastin) Immunogenicity KIT (SS-E-103) Ranibizumab (Lucentis) Immunogenicity KIT (SS-E-104) Trastuzumab (Herceptin) Immunogenicity KIT (SS-E-105)

PK ELISA KITS

```
Infliximab (Remicade ) PK ELISA KIT (SS-E-106)
Infliximab (Remicade ) PK ELISA KIT (SS-E-107)
Adalimumab (Humira ) PK ELISA KIT (SS-E-108)
Adalimumab (Humira ) PK ELISA KIT (SS-E-109)
Etanercept (Enbrel ) PK ELISA KIT (SS-E-110)
Rituximab (Mabthera ) PK ELISA KIT (SS-E-111)
Ranibizumab (Lucentis ) PK ELISA KIT (SS-E-112)
Trastuzumab (Herceptin ) PK ELISA KIT (SS-E-113)
```



CYTOKINE & HCP KITS


Human TNF alpha ELISA KIT (SS-E-114) Human TNF alpha ELISA KIT (SS-E-115), Without Pre-coated Plate DeQuantoTM E. Coli HCP ELISA KIT (SS-E-116) DeQuantoTM CHO HCP ELISA KIT (SS-E-116)



PRODUCTS FROM OUR PARTNER (Antibody Research corporation, USA)

HyMax[™] SF Hybridoma Fusion & Cloning Supplement Serum Free 20x

Third party independent comparisons of HyMax to other products:





CELL LINES FOR RESEARCH AND DEVELOPMENT

(Antibody Research corporation, USA)

Ag8 Cells (Mouse Myeloma) BHK21 cell line (hamster kidney cells) BW1100 (T cell Thymoma) CaCO2 cell line (human colorectal adenocarcinoma) CHO cell line (hamster ovary cells) COS1 cell line (monkey SV40 transformed kidney cells) Daudi cell line (human lymphoma, Burkitt) EL4 cell line (mouse lymphoma) HaCaT cell line (human keratinocytes) HEK293 cell line (human embryonic kidney) HeLa cell line (human cervical carcinoma) Hep2 cell line (human larynx squamous cell carcinoma) HepG2 cell line (human hepatocellular carcinoma) HT-2 (mouse T cells) Huv-Ec-C cell line (human vascular endothelium) <u>J774.1 cell line (mouse monocyte/macrophage)</u> Jurkat cell line (human T cell leukemia) K562 cell line (human chronic myelogenous leukemia) KB cell line (human) L929 cell line (mouse subcutaneous connective tissue)

CUSTOMIZED INSTRUMENTS FROM SARSUAG



Incubator Cat.No: SS-I-105



UVHL Portable Lamp



UVS Ultra Portable Lamp Cat.No : SS-I-106



Vertical Gel Electrophoresis Unit (SDS - PAGE)





Electrophoresis system Cat. No : SS-I-101



Gel Rocker Cat. No : SS-I-103



UV Transilluminator Cat. No : SS-I-102



PCR Work Hood Cat. No : SS-I-104





Rotary evaporator Cat.No : SS-I-109



Overhead stirrer Cat.No : SS-I-111



Magnetic stirrer Cat.No : SS-I-110



Micro centrifuge Cat.No : SS-I-112 & Cat.No : SS-I-113







LCD digital shaker Cat.No : SS-I-114



LCD digital rotator Cat.No : SS-I-116



Micro plate Mixer Cat.No : SS-I-



LCD digital tube roller Cat.No : SS-I-117





Programmable Power Supplies Cat.No : SS-I-118



Autoclaves Horizontal : SS-I-



Autoclaves Vertical : SS-I-119



Circulating Water Baths : Cat.No : SS-I-121





Humidity / Stability Chambers Cat.No : SS-I-122



Programmable Oven : SS-I-



Cryo Box (Any Size) : SS-I-123



Bio-Safety Cabinets : Cat.No : SS-I-125





Stackable Refrigerated Incubator Shaker Cat.No : SS-



Hygene Bioreactor / Fermentor



UV/VIS Spectrophotometer Cat.No: SS-I-127



CO2 Incubator : Cat.No : SS-I-





Refrigerated Centrifuge Cat.No : SS-I-130



Sonicator : SS-I-132

Freeze Dryer - Lyophilizer Cat.No: SS-I-131

Compact & Multitask Lyophilizer



Freeze Dryer

Ice Flake Machine : Cat.No : SS-I-







Double Decker Refrigerated Shaker Cat.No : SS-I-134



Incubator Shaker : SS-I-136



Refrigerated Shaker – Advance Model



Ultrasonic Bath : Cat.No : SS-I-137





PHD RESEARCH WORK

- We undertake PhD research work in field of Molecular Biology, Immunology , Biophysics and Molecular Biology.
- We also train researcher and scientist on different techniques like stem cell therapy and novel drug delivery system.
- We encourage researcher to published national and International Journal.



Why Sarsuag Enterprises ??

- > One stop shop for all biology solutions and Lab Instruments
- Flexible service model to meet your requirements
- Offsite development without burdening customers infrastructure

$\sqrt{Our Values}$

- Quality
- ➤ Speed
- ➢ Integrity

 \sqrt{We} provide best science for your business





Pharma & Biotech

Intas Biopharma, Ahmedabad Zydus Cadila, Ahmedabad Sun Pharma, Vadodara Unichem Laboratories, Goa Biocon, Bangalore

Global Solution Providers

Antibody Research corporation, USA

Our Partners

Antibody Research corporation<u>, USA</u> Liveon Biolabs Pvt. Ltd. Bangalore



Thank You

SARSUAG ENTERPRISES

Door no. H.No58/5, opposite Corporation bank Adukkambarai, Arni main road Mettupalayam village, Vellore – 632011, TEL NO : +91 9741303968 TAMILNADU, INDIA Website: www.sarsuagenterprises.com

For Further information, contact:

info@sarsuagenterprises.com